[go: up one dir, main page]

UA88648C2 - Inhibitors of c-fms kinase - Google Patents

Inhibitors of c-fms kinase

Info

Publication number
UA88648C2
UA88648C2 UAA200704498A UAA200704498A UA88648C2 UA 88648 C2 UA88648 C2 UA 88648C2 UA A200704498 A UAA200704498 A UA A200704498A UA A200704498 A UAA200704498 A UA A200704498A UA 88648 C2 UA88648 C2 UA 88648C2
Authority
UA
Ukraine
Prior art keywords
cancer
diseases
treating
compounds
formula
Prior art date
Application number
UAA200704498A
Other languages
English (en)
Ukrainian (uk)
Inventor
Карл Иллиг
Шелли К. Баллентайн
Джиншенг Чен
Санат Меегалла
М. Рудольф
Марк УОЛЛ
Кен Уилсон
Рене Десжарле
Кристофер Моллой
Карл Менти
Кристофер Флорес
Original Assignee
Янссэн Фармацэвтика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссэн Фармацэвтика Н.В. filed Critical Янссэн Фармацэвтика Н.В.
Publication of UA88648C2 publication Critical patent/UA88648C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

Изобретение относится к соединениям Формулы (І), где А, X, Rи W определены в описании, а также к их сольватам, гидратам, таутомерам и фармацевтически приемлемых солей, которые ингибируют протеинтирозинкиназы, особенно c-fms киназу.Также описаны способы лечения аутоиммунных болезней и болезней с воспалительным компонентом; лечение метастаза, который является результатом рака яичников, рака маточных труб, рака молочной железы, рака толстой кишки, рака желудка, лейкоза ворсистых клеток и немелкоклеточной карциномы легкого; и лечения боли, включая скелетную боль, вызванную метастазом опухолей или остеоартритом, или висцеральной, воспалительной и нейрогенной болью; а также остеопороза, болезни Пагета и других болезней, в которых ресорбция кости обуславливает забол�
UAA200704498A 2004-10-22 2005-10-20 Inhibitors of c-fms kinase UA88648C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62121104P 2004-10-22 2004-10-22

Publications (1)

Publication Number Publication Date
UA88648C2 true UA88648C2 (en) 2009-11-10

Family

ID=36228272

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200704498A UA88648C2 (en) 2004-10-22 2005-10-20 Inhibitors of c-fms kinase

Country Status (18)

Country Link
EP (1) EP1807077B1 (ru)
JP (1) JP5046950B2 (ru)
KR (1) KR101273434B1 (ru)
CN (1) CN101437514B (ru)
AU (1) AU2005299837A1 (ru)
BR (1) BRPI0516947A (ru)
CA (1) CA2585053C (ru)
DK (1) DK1807077T3 (ru)
EA (1) EA013250B1 (ru)
ES (1) ES2611604T3 (ru)
HU (1) HUE033089T2 (ru)
MX (1) MX2007004784A (ru)
NO (1) NO339555B1 (ru)
PL (1) PL1807077T3 (ru)
PT (1) PT1807077T (ru)
UA (1) UA88648C2 (ru)
WO (1) WO2006047277A2 (ru)
ZA (1) ZA200704106B (ru)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790724B2 (en) 2003-04-25 2010-09-07 Janssen Pharmaceutica N.V. c-fms kinase inhibitors
US7427683B2 (en) 2003-04-25 2008-09-23 Ortho-Mcneil Pharmaceutical, Inc. c-fms kinase inhibitors
EP1631560A2 (en) 2003-04-25 2006-03-08 3-Dimensional Pharmaceuticals, Inc. C-fms kinase inhibitors
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
WO2006047504A1 (en) * 2004-10-22 2006-05-04 Janssen Pharmaceutica, N.V. Aromatic amides as inhibitors of c-fms kinase
CA2598423C (en) 2005-02-18 2014-05-27 Astrazeneca Ab Antibacterial piperidine derivatives
US20080269214A1 (en) * 2005-03-04 2008-10-30 Astrazeneca Ab Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors
EP1888549A2 (en) 2005-05-19 2008-02-20 Vertex Pharmaceuticals, Inc. Biaryls useful as modulators of ion channels
WO2006130493A2 (en) 2005-05-31 2006-12-07 Vertex Pharmaceuticals Incorporated Heterocycles useful as modulators of ion channels
US20070004660A1 (en) * 2005-06-10 2007-01-04 Baumann Christian A Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
CN101340909B (zh) * 2005-10-18 2012-01-11 詹森药业有限公司 抑制flt3激酶的方法
CN101610768B (zh) * 2006-04-20 2012-03-21 詹森药业有限公司 抑制c kit激酶的方法
JP5089681B2 (ja) 2006-04-20 2012-12-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ｃ−ｆｍｓキナーゼの阻害剤としての複素環式化合物
AU2006342509A1 (en) * 2006-04-20 2007-11-01 Janssen Pharmaceutica, N.V. c-fms kinase inhibitors
US8697716B2 (en) * 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
CA2650057C (en) 2006-04-20 2014-07-29 Janssen Pharmaceutica N.V. Phenyl- or pyridinyl-amide as inhibitors of c-fms kinase
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
JP5443342B2 (ja) 2007-06-08 2014-03-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ピペリジン／ピペラジン誘導体
CN101678019B (zh) 2007-06-08 2016-03-30 詹森药业有限公司 哌啶/哌嗪衍生物
ES2483898T3 (es) 2007-06-08 2014-08-08 Janssen Pharmaceutica, N.V. Derivados de piperidina/piperazina
AU2013203813B2 (en) * 2007-10-17 2014-07-31 Janssen Pharmaceutica, N.V. Inhibitors of C-FMS kinase
JO3240B1 (ar) * 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
WO2009058801A1 (en) * 2007-11-02 2009-05-07 Janssen Pharmaceutica, N.V. Use of cfms inhibitor for treating or preventing bone cancer and the bone loss and bone pain associated with bone cancer
TWI498115B (zh) 2007-12-27 2015-09-01 Daiichi Sankyo Co Ltd 咪唑羰基化合物
WO2009147170A2 (en) 2008-06-05 2009-12-10 Janssen Pharmaceutica Nv Drug combinations comprising a dgat inhibitor and a ppar-agonist
WO2011149841A1 (en) 2010-05-25 2011-12-01 Janssen Pharmaceutica Nv SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-α MODULATORS
EP2822656B1 (en) 2012-03-07 2016-10-19 Institute of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
EP2882757B1 (en) 2012-08-07 2016-10-05 Janssen Pharmaceutica, N.V. Process for the preparation of heterocyclic ester derivatives
CA2879176C (en) * 2012-09-17 2020-10-27 F.Hoffmann-La Roche Ag Triazole carboxamide derivatives
CN103664957A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
CN103804349A (zh) * 2012-11-01 2014-05-21 杨子娇 一类治疗青光眼的化合物及其用途
CN104370880A (zh) * 2013-01-24 2015-02-25 韩冰 一类蛋白酶抑制剂及其制备方法和用途
CN104370881A (zh) * 2013-01-24 2015-02-25 韩冰 一类具有神经保护作用的化合物及其制备方法和用途
CN104370882A (zh) * 2013-01-24 2015-02-25 韩冰 一类降低眼压的化合物及其制备方法和用途
HUE036925T2 (hu) 2013-03-15 2018-08-28 Janssen Pharmaceutica Nv C-fms kináz inhibitorként használható helyettesített piridin származékok
EP3024832B1 (en) 2013-07-22 2018-03-28 Idorsia Pharmaceuticals Ltd 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives
AU2014320149A1 (en) 2013-09-11 2016-04-07 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
MA41337A (fr) 2015-01-15 2017-11-22 Idorsia Pharmaceuticals Ltd Dérivés de l'hydroxyalkyl pipérazine utilisés comme modulateurs du récepteur cxcr3
JP7012822B2 (ja) * 2017-08-10 2022-02-14 中国科学院上海薬物研究所 フタラジノン系化合物、その製造方法、医薬組成物及びその使用
US10930064B2 (en) 2018-02-08 2021-02-23 Covidien Lp Imaging reconstruction system and method
WO2020127200A1 (en) 2018-12-17 2020-06-25 Tolremo Therapeutics Ag Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
WO2021144360A1 (en) 2020-01-17 2021-07-22 F. Hoffmann-La Roche Ag Small molecule csf-1r inhibitors in therapeutic and cosmetic uses
WO2024254440A1 (en) * 2023-06-09 2024-12-12 Modulo Bio, Inc. 5-cyano-1h-imidazole-2-carboxamide compounds as csf1r inhibitors
WO2026010948A1 (en) 2024-07-01 2026-01-08 Otsuka America Pharmaceutical, Inc. Compounds useful for the treatment of disorders and methods related thereto

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
CA2336848A1 (en) * 1998-07-10 2000-01-20 Merck & Co., Inc. Novel angiogenesis inhibitors
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
DK1140938T3 (da) * 1999-01-11 2003-12-22 Univ Princeton Højaffinitetsinhibitorer for målvalidering og anvendelser heraf
AU2735201A (en) 1999-12-28 2001-07-09 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
WO2003099796A1 (en) * 2002-05-23 2003-12-04 Cytopia Pty Ltd Protein kinase inhibitors
KR20120032574A (ko) * 2002-10-03 2012-04-05 탈자진 인코포레이티드 혈관항상성 유지제 및 그의 사용 방법
EP1631560A2 (en) * 2003-04-25 2006-03-08 3-Dimensional Pharmaceuticals, Inc. C-fms kinase inhibitors
US20050113566A1 (en) * 2003-04-25 2005-05-26 Player Mark R. Inhibitors of C-FMS kinase
WO2006047504A1 (en) * 2004-10-22 2006-05-04 Janssen Pharmaceutica, N.V. Aromatic amides as inhibitors of c-fms kinase
CN101340909B (zh) * 2005-10-18 2012-01-11 詹森药业有限公司 抑制flt3激酶的方法

Also Published As

Publication number Publication date
EP1807077A2 (en) 2007-07-18
KR101273434B1 (ko) 2013-06-11
NO20072489L (no) 2007-06-29
MX2007004784A (es) 2007-09-11
DK1807077T3 (en) 2017-01-23
EA200700918A1 (ru) 2008-06-30
AU2005299837A1 (en) 2006-05-04
PT1807077T (pt) 2017-01-06
JP2008517926A (ja) 2008-05-29
JP5046950B2 (ja) 2012-10-10
EP1807077A4 (en) 2011-09-21
BRPI0516947A (pt) 2008-09-23
CN101437514B (zh) 2012-04-25
EP1807077B1 (en) 2016-11-23
PL1807077T3 (pl) 2017-05-31
WO2006047277A3 (en) 2009-05-07
ES2611604T3 (es) 2017-05-09
ZA200704106B (en) 2009-09-30
WO2006047277A2 (en) 2006-05-04
KR20070085382A (ko) 2007-08-27
EA013250B1 (ru) 2010-04-30
CN101437514A (zh) 2009-05-20
CA2585053A1 (en) 2006-05-04
CA2585053C (en) 2011-07-12
NO339555B1 (no) 2017-01-02
HUE033089T2 (en) 2017-11-28

Similar Documents

Publication Publication Date Title
UA88648C2 (en) Inhibitors of c-fms kinase
UA93085C2 (en) Inhibitors of c-fms kinase
JO3240B1 (ar) c-fms مثبطات كيناز
PT2021335E (pt) Compostos heterocíclicos como inibidores de c-fms quinase
ATE437864T1 (de) Aromatische amide als hemmer der c-fms-kinase
ECSP077409A (es) Inhibidores de la c-fms cinasa
EA201400575A1 (ru) Способы получения ингибиторов jak киназ и родственных промежуточных соединений
ES2667847T3 (es) Pirimidinas sustituidas útiles como inhibidores de cinasa de EGFR-T790M
IN2014DN06567A (ru)
MXPA05011643A (es) 5,7-diaminopirazolo[4,3-d]pirimidinas en el tratamiento de hipertension.
GEP201706639B (en) Heterocyclic compounds and uses thereof
NZ600631A (en) Heteroaryl compounds and uses thereof
NZ594383A (en) Aminopyrimidines useful as kinase inhibitors
EA018512B1 (ru) Производные пирроло[2,3-d]пиримидина в качестве ингибиторов протеинкиназы в
IL163781A0 (en) Purine derivatives as kinase inhibitors
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.
MX339583B (es) Inhibidores de tirosina cinasa de bruton.
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
MXPA05007607A (es) Inhibidores amida y ester de la metaloproteinasa de matriz.
CA2992403A1 (en) Method for manufacturing nitrogen-containing heterocyclic compound and intermediate of same
TW200602348A (en) Thieno[3, 2-b]pyridine-6-carbonitriles as protein kinase inhibitors
UA90659C2 (ru) Аналоги хиназолина как ингибиторы рецепторных тирозинкиназ
UA85701C2 (ru) Способ получения ингибиторов триптазы
TH148533A (th) ตัวยับยั้ง c-fms ไคเนส
SI1756046T1 (sl) Aril alkil sulfonamidi kot terapevtska sredstva za zdravljenje kostnih stanj